Mapping of catecholaminergic denervation, neurodegeneration, and inflammation in 6-OHDA-treated Parkinson's disease...

Area of Science:

• Neuroscience
• Pathology
• Animal Models

Background:

• Parkinson's disease (PD) research is limited by animal models that don't fully capture disease complexity.
• Existing models often overlook extra-nigrostriatal regions crucial for early non-motor PD symptoms.
• The 6-hydroxydopamine (6-OHDA) mouse model is widely used but primarily studied for its nigrostriatal effects.

Purpose of the Study:

• To comprehensively characterize the spatiotemporal effects of 6-OHDA infusion on tyrosine hydroxylase-positive neurons and fibers across the brain.
• To investigate sex differences, disease progression, neuroinflammation, and apoptosis in response to varying 6-OHDA dosages.
• To establish a detailed map of neuronal degeneration and neuroinflammation onset in a widely used PD model.

Main Methods:

• Unilateral 6-OHDA infusion into the dorsal striatum of C57BL/6 mice.
• Immunolabeling and advanced brain clearing techniques (iDISCO+) for whole-brain imaging.
• Light sheet microscopy, functional MRI (fMRI), and machine learning for data analysis.
• Assessment of varying 6-OHDA dosages (5, 10, 20 µg) and recovery times (1, 7, 14 days).

Main Results:

• Detailed mapping of tyrosine hydroxylase-positive neuron and fiber loss extending beyond the nigrostriatal pathway.
• Characterization of the time course of neuronal degeneration and the initiation of neuroinflammatory responses.
• Identification of potential sex-based differences in the pathological cascade following 6-OHDA administration.

Conclusions:

• The 6-OHDA model induces widespread pathology, impacting regions beyond the nigrostriatum, which is critical for understanding PD.
• This study provides a detailed spatiotemporal framework for 6-OHDA-induced neurodegeneration and neuroinflammation.
• Findings offer valuable insights for developing more effective, disease-modifying treatments for Parkinson's disease.